首页|Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connate extract

Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connate extract

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Pulmonary fibrosis(PF)is a chronic progressive end-stage lung disease.However,the mechanisms un-derlying the progression of this disease remain elusive.Presently,clinically employed drugs are scarce for the treatment of PF.Hence,there is an urgent need for developing novel drugs to address such diseases.Our study found for the first time that a natural source of Prismatomeris connata Y.Z.Ruan(Huang Gen,HG)ethyl acetate extract(HG-2)had a significant anti-PF effect by inhibiting the expression of the transforming growth factor beta 1/suppressor of mothers against decapentaplegic(TGF-β1/Smad)pathway.Network pharmacological analysis suggested that HG-2 had effects on tyrosine kinase phosphorylation,cellular response to reactive oxygen species,and extracellular matrix(ECM)disassembly.Moreover,mass spec-trometry imaging(MSI)was used to visualize the heterogeneous distribution of endogenous metabolites in lung tissue and reveal the anti-PF metabolic mechanism of HG-2,which was related to arginine biosyn-thesis and alanine,asparate and glutamate metabolism,the downregulation of arachidonic acid meta-bolism,and the upregulation of glycerophospholipid metabolism.In conclusion,we elaborated on the relationship between metabolite distribution and the progression of PF,constructed the regulatory metabolic network of HG-2,and discovered the multi-target therapeutic effect of HG-2,which might be conducive to the development of new drugs for PF.

Spatially resolved metabolomicsMass spectrometry imagingNetwork pharmacologyPulmonary fibrosisPrismatomeris connate extract

Haiyan Jiang、Bowen Zheng、Guang Hu、Lian Kuang、Tianyu Zhou、Sizheng Li、Xinyi Chen、Chuangjun Li、Dongming Zhang、Jinlan Zhang、Zengyan Yang、Jiuming He、Hongtao Jin

展开 >

New Drug Safety Evaluation Center,Institute of Materia Medico,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing,100050,China

State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100050,China

School of Biomedical Sciences,Hunan University,Changsha 410082,China

College of Pharmacy,Shaanxi University of Traditional Chinese Medicine,Xianyang,Shaanxi,712046,China

Guangxi International Zhuang Medicine Hospital,Nanning 530201,China

State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences &Peking Union Medical College,Beijing,100050,China

Key Laboratory for Safety Research and Evaluation of Innovative Drug,National Medical Products Administration,Beijing,102206,China

Beijing Union-Genius Pharmaceutical Technology Development Co.,Ltd.,Beijing,100176,China

展开 >

2024

10.1016/j.jpha.2024.100971

药物分析学报(英文)
西安交通大学

药物分析学报(英文)

影响因子：0.244
ISSN：2095-1779
年,卷(期)：2024.14(9)